On the Incidence of Pulmonary Embolism
in Spinal Arthrodesis and the Need for
Better Evidence and Prevention Guidelines
Introduction

higher incidences are underpowered and focus
only on high-risk patients. These discrepancies
in the literature highlight the need for largerscale studies inclusive of patients of all risk
stratifications in order to accurately determine
the overall incidence of PE after spinal fusion.

Literature Review

Studies that focus on spinal fusion indicated
for trauma generally report a higher incidence
of PE than studies focused on elective or nontrauma spinal fusions.10,14,15,17 No study directly
compares trauma versus non-trauma groups,
however. A study directly comparing the incidence of PE in non-trauma and trauma spinal
fusion patients would be useful to confirm that
trauma patients do in fact have higher risks for
PE, and might encourage additional prophylaxis and stricter observation in this population.
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Pulmonary Embolism (PE) is a rare but serious event that may occur after spinal surgery. Vascular
endothelial damage during surgery and immobilization of the patient after surgery contribute to
a higher risk of thrombosis and subsequent PE.6 Prophylaxis including intermittent pneumatic
compression stockings, heparin, and other interventions is often employed by the treatment team
to lower the risk of thromboembolic complications. In orthopedic, trauma, burn and other high-risk
surgical patients, the incidence of PE has been thoroughly studied, and this knowledge has been used
to establish prophylaxis guidelines specifically for these patients.7 The incidence of PE in spinal fusion
patients, however, is less well studied, and definitive prophylaxis guidelines are lacking. The aim of
this article is to review what is known about the incidence of PE in spinal arthrodesis patients, and
describe the need for better medical evidence and prevention guidelines on this issue.
Smith et al,17 in the largest published study, reported on 108,419 patients undergoing lumbar
microdiscectomy, anterior cervical discectomy and fusion, and lumbar stenosis decompression
procedures. They reported a PE incidence of 0.14%. Only one other study, a meta analysis, acheived
a sample size greater than 1,000 (Table 1). This study by Sansone et al15 reported a PE incidence
of 0.06% in elective spinal fusion patients. In a study by Schizas et al,16 270 spinal fusion patients
were given heparin prophylaxis and 2.2% developed PE.
Although other studies had limited sample sizes, they address more specific sub-groups of spinal
arthrodesis patients. Platzer et al14 studied 978 patients that were admitted to a level-1 trauma center
and subsequently underwent spinal fusion for traumatic indications and noted a PE incidence of
0.92%. McKinley et al10 further studied 779 spinal cord injury (SCI) patients and reported the highest incidence of PE at 2.0%. In a group of patients determined to be at high risk for PE, Leon et al9
placed prophylactic inferior vena cava filters after spinal fusion surgery and reported a subsequent
PE incidence of 1.4% in these patients.
Several studies have identified an association between spinal surgical approach and the incidence
of PE. Pateder et al12 followed 407 spinal patients and noted a PE incidence of 0.65% with posterior
approach and 4.5% with anterior or combined anterior-posterior approach. Kim et al8 studied
119 patients and reported an incidence of 1.6% with posterior approach and 7.5% with combined
anterior-posterior approach. Dearborn et al3 studied 116 patients and reported an incidence of
0.5% with posterior approach and 6.0% with combined anterior-posterior approach. Epstein et
al4 reported an incidence of 1.5% with anterior approach, Cho et al1 reported an incidence of
2.1% with posterior approach, and Piasecki et al13 reported an incidence of 7.6% with combined
anterior-posterior approach, although these studies did not directly compare different approaches.
Other studies examined the incidence of PE after spinal fusion in specific surgical regions. Oskouian
et al11 studied 207 patients and reported a PE incidence of 0.48% in thoracolumbar fusions, while
Wood et al19 studied 136 patients and reported an incidence of 0.70% with thoracolumbar fusions.
Neither study directly compared the PE incidence in different spinal regions.
Discussion
The incidence of PE in spinal fusion patients is reported in the range of 0.06% – 7.6%. This confirms
that PE is a rare event in these patients, but occurs often enough to warrant attention from the medical team. The range of reported incidences, however, is wide. The only large-scale study17 reported an
incidence of 0.14%, but studied a specific group of low risk patients. Other studies that report much
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Likewise, studies that focus on PE incidence
depending on the approach to spinal fusion
surgery report a higher incidence in combined
anterior/posterior approach than in anterior
or posterior approaches alone.3,8,12 This link,
however, is not well established in the literature
because few studies compare approaches accurately and those that do are underpowered. To
establish a link between surgical approach and a
higher incidence of PE, larger studies are necessary. Furthermore, PE incidence also may vary
depending on the region of spinal fusion, but
too few studies have been published to suggest
a relationship.
Over the past decades, several guidelines
concerning the management of venous thromboembolism and PE prophylaxis have
been produced, such that at present, many
spinal fusion patients receive postoperative
anticoagulation, compression devices, and
elastic stockings.2,5,7,18 However it is unclear
in the literature how these advancements in
prophylactic guidelines and treatments have
affected the incidence of PE in spinal fusion
patients over time. At present there is little
published longitudinal data assessing these
effects. A recent analysis at our institution
using the Nationwide Inpatient Sample showed
that despite these medical advancements, the
incidence of PE in spinal fusion patients has
steadily remained about 0.2% since 1988.20

Spine

Table 1. Studies of Pulmonary Embolism Incidence in Spinal Arthrodesis Patients
Author
JS Smith, et al.
JM Sansone, et al.

Number of Patients
108,419
4,383

Procedure/indication

Incidence %

Lumbar microdiscectomy, anterior cervical discectomy and fusion, lumbar
stenosis decompression

0.14%

Elective spinal fusion

0.06%

P Platzer, et al.

978

Spinal fusion after trauma

0.92%

W McKinley, et al.

779

Spinal fusion after spinal cord injury

2.00%

DB Pateder, et al.

407

Reconstructive spinal fusion

2.40%

Posterior approach

0.65%

Anterior and Anterior/Posterior approach

4.50%

MD Smith, et al.

317

Reconstructive spinal fusion

0.32%

C Schizas, et al.

270

All fusions

2.20%

Anterior and Anterior/Posterior lumbar or thoracolumbar fusion

4.20%

RJ Oskouian Jr., et al.

207

Anterior thoracolumbar spinal fusion

0.48%

NE Epstein, et al.

200

Anterior approach

1.50%

KB Wood, et al.

136

Thoracolumbar reconstruction

0.70%

HJ Kim, et al.

119

Posterior Approach

1.60%

Anterior/Posterior approach

7.50%

All fusions

2.20%

Posterior approach

0.50%

Anterior/Posterior approach

6.00%

JT Dearborn, et al.

116

L Leon, et al.

74

“High-risk” spinal fusion

1.40%

DP Piasecki, et al.

66

Anterior/Posterior approach

7.60%

KJ Cho, et al.

47

Posterior approach

2.10%

Further analysis is necessary to determine if the
current prophylaxis guidelines and treatments
are adequate.

Conclusion

Pulmonary embolism (PE) is a rare and dreaded
event that may occur after spinal fusions, the
incidence of which is reported in the literature
between 0.06%-7.6%. Though some studies report
a higher incidence of PE in trauma patients and
those undergoing a combined anterior/posterior
procedure, more complete and higher powered
investigations are necessary to confirm these findings. Longitudinal studies are lacking, and will be
necessary to determine if PE prophylaxis in spinal
fusion patients has been effective in the long term.
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At Jefferson Hospital for
Neuroscience, neurologist Michael
M. Moussouttas, MD, and nurse
Lauren Dougherty use the Jefferson
Expert Teleconsulting (JET) system to
consult with Robert H. Rosenwasser,
MD, FACS, Chair, Department of
Neurological Surgery (pictured on
monitor), who is at another location.

Pioneering Leading-Edge Treatments
Jefferson Hospital for Neuroscience staff have helped to
develop and/or have introduced to the region leadingedge treatments and technologies that reduce the need
for open brain surgery for stroke, brain aneurysms and
AVMs. Among them:
• Intra-arterial thrombolysis with tPA – pharmacological
blood clot-dissolving
• Mechanical thrombectomy devices – e.g., Merci
Retrieval System®
• Wingspan stent – FDA-approved mesh tube to open
blocked arteries in the brain after clot-dissolving drugs
have failed
• Coiling, gluing and stenting of brain aneurysms –
reduces need for open brain surgery

Announcing Jefferson’s Teleconsulting (JET) Robotic System for Help with
Diagnosis and Treatment of Time-Sensitive Neurovascular Diseases
“Time is brain” is the credo among healthcare
professionals for diagnosing and treating timesensitive neurovascular diseases, including arteriovenous malformations (AVMs), brain aneurysms and,
especially, stroke. The blood-clot busting medication
tissue plasminogen activator (tPA), for example, must
be administered to a patient having a stroke within
4.5 hours for best chance of functional recovery.
Timely performance of neurosurgical procedures
to remove AVMs and aneurysms are similarly
urgent. Yet many community hospitals have limited
experienced staff and technology to diagnose and
treat patients quickly and accurately.
Now, to provide sophisticated care and expertise
to patients at hospital emergency rooms in small
community hospitals in distant areas of eastern
Pennsylvania, south and central New Jersey, and
Delaware, Jefferson Hospital for Neuroscience
(JHN) in Philadelphia is launching Jefferson Expert
Teleconsulting (JET), the region’s first university-based
high-tech mobile robotic system for neuroscience.
“JET places all of our resources – among them, dualtrained neurosurgeons, advanced technology, and
leading-edge clinical trials in which we partner with the
National Institutes of Health – at the disposal of patients,
their families and physicians in need of a second, expert
opinion,” says Robert H. Rosenwasser, MD, FACS,
Professor and Chair, Department of Neurological
Surgery, JHN and Jefferson Medical College of Thomas
Jefferson University. “Its greatest value is for timely
diagnosis and application of treatment for time-sensitive
neurovascular diseases, especially stroke.”
Enhancing level of care
“We want to partner with hospitals in other
communities to help advance stroke care throughout

the region. As the leading provider of stroke care
in the region, we have an obligation to do that,”
adds Pamela Kolb, Vice President, Neuroscience
Service, JHN.
Supported by Thomas Jefferson University, a
leading academic center, JHN is the region’s only
dedicated hospital for neuroscience and leading,
most experienced and comprehensive center for
diagnosis and treatment of stroke and cerebrovascular
disease. JHN’s Acute Stroke Center is the largest such
facility, with more board-certified neurocritical care
physicians than most, in the greater Delaware Valley.
It is also a Joint Commission-accredited primary
stroke center.
“Stroke is the third-leading cause of death in the
United States but the leading cause of disability, by a
factor of five over any other disease,” Dr. Rosenwasser
notes. “Given its prevalence and time-sensitive nature,
it is alarming how few people receive treatment in the
appropriate amount of time. With JET, even hospitals
in remote areas can provide patients with expert
consultation and disposition of appropriate care from
an experienced neurologist or neurological surgeon
immediately in cases where every minute can make a
critical difference. It’s a very cost-effective approach to
providing 24/7 onsite coverage and expertise.”
How JET works
Each participating hospital is supplied with a mobile
robotic platform, manufactured by InTouch Health®
of Santa Barbara, CA, that enables the JHN Network
physician to be remotely present. JET’s panoramic
visualization system and easy-to-use control interface
afford physicians, patients and hospital staff a safe and
effective interactive experience.

InTouch’s remote presence devices are the first and
only with FDA approval. The robots allow direct
connection to medical devices such as electronic
stethoscopes, otoscopes and ultrasound to transmit
medical data to the remote physician.
“Should a patient arrive in the ER of a hospital that’s
located, say, three hours away from Jefferson and
either doesn’t have a neurologist or neurosurgeon
available or has a neurologist who needs to consult
with a neurosurgeon,” Dr. Rosenwasser, explains, “the
attending physician contacts JHN. The JHN Network
specialist on call then uses a laptop to connect to
the remote hospital via the robot, obtain a medical
history by speaking directly with the patient and/or
family members, examine the patient and determine
what therapy is immediately needed, in real time,
without delay. Finally, a decision is made either to
admit the patient to the local hospital’s Critical Care
Unit or transfer him or her to the Jefferson Acute
Stroke Center, by JeffSTAT, Jefferson’s transport
service, or the hospital’s own service.”
“Patients may not need to be transferred – they can
stay in their own community and be treated very
successfully there, thanks to this program,” says Ms.
Kolb. “And most patients want to stay close to home.
JET enables them to receive sophisticated medical
care without having to travel long distances.”
“It also serves as an educational program,” adds Dr.
Rosenwasser. “As a teaching center, JHN will use
JET to share our clinical protocols with participating
hospitals so that they can enhance stroke care within
their communities. On the other hand, should the
patient need an advanced neurosurgical procedure
[See sidebar], we can arrange for prompt transfer.”

JHN continues to set the standard worldwide
for state-of-the-art care for time-sensitive
neurovascular diseases. For more information
about these and other treatments, visit
www.JeffersonHospital.org/neuroscience.
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